CY1107944T1 - Χρησεις του μπορρελιοκτονου επιτοπου (-ων) της πρωτεϊνης c εξωτερικης επιφανειας borrelia burgdorferi (ospc) σαν εμβολιο - Google Patents

Χρησεις του μπορρελιοκτονου επιτοπου (-ων) της πρωτεϊνης c εξωτερικης επιφανειας borrelia burgdorferi (ospc) σαν εμβολιο

Info

Publication number
CY1107944T1
CY1107944T1 CY20081100502T CY081100502T CY1107944T1 CY 1107944 T1 CY1107944 T1 CY 1107944T1 CY 20081100502 T CY20081100502 T CY 20081100502T CY 081100502 T CY081100502 T CY 081100502T CY 1107944 T1 CY1107944 T1 CY 1107944T1
Authority
CY
Cyprus
Prior art keywords
ospc
borrelia burgdorferi
borrelic
vaccine
acid surface
Prior art date
Application number
CY20081100502T
Other languages
English (en)
Inventor
Steven N Callister
Steven D Lovrich
Ronald F Schell
Dean A Jobe
Original Assignee
Gundersen Lutheran Medical Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gundersen Lutheran Medical Foundation, Inc. filed Critical Gundersen Lutheran Medical Foundation, Inc.
Publication of CY1107944T1 publication Critical patent/CY1107944T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Ένα πεπτίδιο σύντηξης θραύσματος OspC Dra που απομονώνεται από Borrelia burgdorferi περιγράφεται εδώ για την πρόληψη, θεραπεία και πρώιμη διάγνωση της ασθένειας Lyme σε ανθρώπους και άλλα ζώα. Η εφεύρεση αυτή επίσης αφορά μια μέθοδο συστηματικής εξέτασης που ανιχνεύει αντι-Osp μπορρελιοκτόνου αντισώματος δραστικότητα και αντισώματα που αντιδρούν με ένα θραύσμα πρωτεΐνης που κωδικοποιείται από ένα Dral-Smal DNA θραύσμα της OspC.
CY20081100502T 1998-07-31 2008-05-13 Χρησεις του μπορρελιοκτονου επιτοπου (-ων) της πρωτεϊνης c εξωτερικης επιφανειας borrelia burgdorferi (ospc) σαν εμβολιο CY1107944T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9495598P 1998-07-31 1998-07-31
EP99938897A EP1100922B1 (en) 1998-07-31 1999-07-30 Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine

Publications (1)

Publication Number Publication Date
CY1107944T1 true CY1107944T1 (el) 2013-09-04

Family

ID=22248146

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100502T CY1107944T1 (el) 1998-07-31 2008-05-13 Χρησεις του μπορρελιοκτονου επιτοπου (-ων) της πρωτεϊνης c εξωτερικης επιφανειας borrelia burgdorferi (ospc) σαν εμβολιο

Country Status (13)

Country Link
US (2) US6210676B1 (el)
EP (1) EP1100922B1 (el)
JP (1) JP3631960B2 (el)
AT (1) ATE386805T1 (el)
AU (1) AU5328299A (el)
CA (1) CA2332570C (el)
CY (1) CY1107944T1 (el)
DE (1) DE69938183T2 (el)
DK (1) DK1100922T3 (el)
ES (1) ES2302385T3 (el)
NO (1) NO329227B1 (el)
PT (1) PT1100922E (el)
WO (1) WO2000006745A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
AU5751000A (en) 1999-06-18 2001-01-09 Brook Biotechnologies, Inc. Groups of borrelia burgdorferi and borrelia afzelii that cause lyme disease in humans
ES2298249T3 (es) * 2000-08-18 2008-05-16 Research Foundation Of State University Of New York Ospa modificada de borrelia burgdorferi.
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
PT1311682E (pt) * 2000-08-18 2008-03-11 Brookhaven Sciences Ass Llc Construcões recombinantes de borrelia burgdorferi
EP1865062A3 (en) * 2000-08-18 2008-01-09 Research Foundation Of State University Of New York Altered OspA of Borrelia burgdorferi
US20020142355A1 (en) * 2000-11-14 2002-10-03 Baylor College Of Medicine Methods for the in vivo biotin labeling of polypeptides
SG176451A1 (en) * 2006-11-03 2011-12-29 Schering Plough Ltd Canine lyme disease vaccine
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP2167536A1 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2009135118A2 (en) * 2008-05-02 2009-11-05 Virginia Commonwealth University Lyme disease vaccine
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
BR112013007329A2 (pt) 2010-09-27 2016-07-19 Univ Cornell método para diagnostificar o estado de doença de lyme em um mamífero, e, composição
US8808705B2 (en) * 2010-10-20 2014-08-19 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
US9562079B2 (en) 2012-04-18 2017-02-07 Zoetis Services Llc Vaccines and methods to treat lyme disease in dogs
UY34745A (es) 2012-04-18 2013-11-29 Zoetis Llc Vacunas y procedimientos para tratar la enfermedad de lyme en perros
US11061028B2 (en) 2014-09-24 2021-07-13 Defined Diagnostics, Llc Compositions and methods for the diagnosis of lyme disease
WO2019110486A1 (en) 2017-12-04 2019-06-13 Intervet International B.V. Canine lyme disease vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US5385826A (en) 1989-04-21 1995-01-31 Gundersen Medical Foundation, Ltd. Diagnostic assay for lyme disease
DE4015911A1 (de) 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5912117A (en) 1990-03-07 1999-06-15 Roche Molecular Systems, Inc. Method for diagnosis of lyme disease
SG47447A1 (en) 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
EP0701612B1 (en) 1993-04-29 1998-01-21 IMMUNO Aktiengesellschaft IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS
US5656451A (en) 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
CA2175579A1 (en) * 1993-10-26 1995-05-04 Chang Yi Wang Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US5558993A (en) 1994-06-17 1996-09-24 The Regents Of The University Of California Cloned Borrelia burgdorferi virulence protein
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
WO1997036008A1 (en) 1996-03-26 1997-10-02 Biotechnology Transfer, Inc. Methods for measurement of lymphocyte function
DE896583T1 (de) 1996-05-02 2000-03-09 Statens Seruminstitut Neue osp-c abgeleitete peptidefragmente
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA

Also Published As

Publication number Publication date
CA2332570C (en) 2009-12-08
JP3631960B2 (ja) 2005-03-23
US6210676B1 (en) 2001-04-03
NO20010412D0 (no) 2001-01-24
EP1100922B1 (en) 2008-02-20
DE69938183T2 (de) 2009-02-19
NO329227B1 (no) 2010-09-20
WO2000006745A1 (en) 2000-02-10
DE69938183D1 (de) 2008-04-03
CA2332570A1 (en) 2000-02-10
ATE386805T1 (de) 2008-03-15
PT1100922E (pt) 2008-05-30
NO20010412L (no) 2001-03-29
ES2302385T3 (es) 2008-07-01
JP2002523019A (ja) 2002-07-30
US6464985B1 (en) 2002-10-15
EP1100922A1 (en) 2001-05-23
DK1100922T3 (da) 2008-06-16
AU5328299A (en) 2000-02-21

Similar Documents

Publication Publication Date Title
CY1107944T1 (el) Χρησεις του μπορρελιοκτονου επιτοπου (-ων) της πρωτεϊνης c εξωτερικης επιφανειας borrelia burgdorferi (ospc) σαν εμβολιο
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
MA28418B1 (fr) Anticorps liant un recepteur de l'interleucine 4
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
CY1109423T1 (el) Ανθρωπινα μονοκλωνα αντισωματα αντι-ιντελευκινης-5 και μεθοδοι και συνθεσεις που τα περιεχουν
NO995458L (no) Humane 12-lignende reseptorproteiner, beslektede reagenser og metoder
JP2004501631A5 (el)
DK0853487T3 (da) Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
PE20061444A1 (es) Anticuerpo anti-mcp-1, composiciones, metodos y usos
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
WO2001074904A3 (en) G-protein coupled receptors and nucleic acids encoding same
DK1261712T3 (da) Proteiner benævnt FXTRC og nucleinsyrer kodende for samme
DE60330780D1 (de) Sequenzen des t-zellrezeptors cdr3 und nachweisverfahren
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
WO2001090187A3 (en) G-protein coupled olfactory receptors
DE50111112D1 (de) Hyphenspezifische faktoren aus candida albicans
WO2002059313A3 (en) G-protein coupled receptors and nucleic acids encoding same
WO2001074897A3 (en) Protein amf-1 to amf-10 and nucleic acids encoding the same
WO2002040539A3 (en) Gpcr-like protein and nucleic acids encoding same
WO2001064879A3 (en) G-proteins coupled receptor related polypeptides
WO2001081378A3 (en) G-protein coupled receptors
WO2004000882A3 (en) Proteins
WO2002010202A3 (en) G-protein coupled receptors and nucleic acids encoding same
MX9601346A (es) Antigeno novedoso de trypanosoma cruzi y el gen que codifica para este ultimo; y su aplicacion para la deteccion de la enfermedad de chagas.